Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Axsome Therapeutics Shares Open 82% Higher on Phase 3 MDD Trial Outcome

Axsome Therapeutics shares reached a new 52-week high price today after the company reported that its AXS-05 drug achieved primary endpoint in the GEMINI Phase 3 trial in Major Depressive Disorder. The firm indicated that the positive results support a New Drug Application fil...
Streetwise Reports | December 17, 2019 |

Psychedelic Leader to Advance Mental Health in 2021 with Growth of Clinics, Lab and Partnerships

(Image via Numinus Wellness Inc.) In 2020, Health Canada began allowing select patients to take psilocybin for relief of end-of-life-distress. This was followed by a proposed regulation revision that could allow doctors to prescribe both psilocybin and MDMA for t...
Stockhouse Editorial | January 14, 2021 |

BioNTech, CureVac, Valeo Pharma - the license to print money

Those who solve problems or create desires can usually earn a lot of money. One of the most important requirements is that the solution is scalable and can be sold in large quantities. The solutions around the Corona pandemic are a particularly lucrative business, because ther...
Mario Hose | August 24, 2020 |

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Zynex Shares Trade Higher After Reporting a 95% Increase in Q3 Orders

Non-invasive medical device maker Zynex Inc's. shares are trading 12% higher on an overall down market day after the company reported that Q3/19 orders are up 95% over the same period in 2018. This morning medical technology company specializing in manufacturing and s...
Streetwise Reports | October 3, 2019 |

XPhyto: The Cutting Edge of Medical Cannabis Science

At the forefront of the next wave of cannabis commercialization, is a German-focused company with headquarters in Vancouver, XPhyto Therapeutics Corp. (CSE: XPHY; FSE: 4XT) , that is building a much-coveted cannabis R&D cultivation facility in a converted nuclear bunker and o...
Marc Davis | November 12, 2019 |

The Golden Bullet for Drug Delivery

It’s the Holy Grail in the cannabis industry. Everyone is trying to innovate the best delivery system to optimize the “bioavailability” (uptake) of medical cannabis in order to offer the perfect pairing -- precise dosing with a fast on...
Marc Davis | January 8, 2020 |

Disruptive. Transformative. Empowering. Integrated Digital Care for the Future.

CareSpan Health Inc. ( TSX-V.CSPN , Forum ) is a disruptive, transformative, and empowering company providing a digital healthcare platform that integrates digital care tools, capabilities, and data in one place. The company's proprietary "Clinic-in-the Cloud" is a c...
Dave Jackson | January 24, 2022 |